NCHC

National Coalition On Health Care

  • About Us
    • Members and Supporters
    • Board of Directors
    • Staff
    • Annual Reports
  • Policy
    • COVID-19 Response
    • Make Prescription Drugs More Affordable
    • Eliminate Surprise Medical Billing
    • Make Health Care Affordable and Accessible
    • Promote a High-Value Health Care System that Supports Vulnerable Populations
  • Blog
  • Events
  • Newsroom
    • Press Releases
    • NCHC In The News
    • Policy Correspondence
    • Fact Sheets & Issue Briefs
  • Get Involved
    • Become a Member
    • Become a Funder
    • Career Opportunities & Internships
  • Contact Us

Gilead Rejects Reasonable Approach with $94,500 New Hepatitis C Drug

October 10, 2014 By Larry McNeely

Tweet
Share

“By charging $94,500 for Harvoni, Gilead has made clear that it values Wall Street above the interests of patients, taxpayers, employers, and working families who must shoulder the burden of high health care costs. The company’s refusal to take a more reasonable and moderate approach to pricing cements its status as the poster child for everything that is wrong with pharmaceutical industry pricing.

Gilead’s escalator pricing could undermine the system of health care finance that has supported the biomedical innovation that we all want to continue. Unreasonable pricing not based on value threatens the sustainability of our entire health care system.”

Read John Rother’s blog post.

Read John Rother’s letter to lawmakers urging them to consider value transparency for pharmaceuticals.

See full press release: https://www.nchc.org/gilead-rejects-reasonable-approach-with-94500-new-hepatitis-c-drug

Filed Under: Press Releases

Gilead Rejects Reasonable Approach with $94,500 New Hepatitis C Drug

October 10, 2014 By Larry McNeely

 

 

 

October 10, 2014

Contact:   Greg Galdabini
                  ggaldabini@nchc.org
                  703-989-0832

FDA Approval and Pricing for New Gilead Hep C Treatment

Statement by John Rother, President and CEO of the National Coalition on Health Care

“By charging $94,500 for Harvoni, Gilead has made clear that it values Wall Street above the interests of patients, taxpayers, employers, and working families who must shoulder the burden of high health care costs. The company’s refusal to take a more reasonable and moderate approach to pricing cements its status as the poster child for everything that is wrong with pharmaceutical industry pricing.

Gilead’s escalator pricing strategy could undermine the system of health care finance that has supported the biomedical innovation that we all want to continue. Unreasonable pricing not based on value threatens the sustainability of our entire health care system.”

Read John Rother’s blog post.

Read John Rother’s letter to lawmakers urging them to consider value transparency for pharmaceuticals.

###

The National Coalition on Health Care (NCHC), the oldest and most diverse group working to achieve comprehensive health system reform, is a 501(c)(3) organization representing more than 80 participating organizations, including medical societies, businesses, unions, health care providers, faith-based associations, pension and health funds, insurers and groups representing consumers, patients, women, minorities and persons with disabilities. Member organizations collectively represent – as employees, members, or congregants – over 100 million Americans.

Some members of NCHC do not, or cannot, take positions either on specific legislation, strategies or on any policies outside their respective mission areas. However, all that can, do endorse broad policy positions in support of comprehensive health system change.

Filed Under: Uncategorized

Mission

To bring together key stakeholders in order to achieve an affordable, high-value health care system for patients and consumers, for employers and other payers, and for taxpayers.

Signup for NCHC Newsletter

NCHC Recent Policy Correspondence

  • NCHC STATEMENT ON BICAMERAL AND BIPARTISAN SURPRISE BILLING LEGISLATION, “NO SURPRISES ACT,”
  • NCHC STATEMENT ON PART D REBATE SAFE HARBOR REPEAL AND “MOST FAVORED NATION” DEMONSTRATION
  • NCHC Statement On The Trump Administration’s “Most-Favored-Nation” Drug Pricing Executive Order
  • NCHC Statement on the Trump Administration’s Executive Orders
  • NCHC Statement on the Pricing of Remdesivir
...More Policy Correspondence

National Coalition on Health Care

About Us

The National Coalition on Health Care (NCHC) was formed more than two decades ago to help achieve comprehensive health system change and is currently led by John Rother. We aim to be a leader in promoting a healthy population and a more effective, efficient and responsive health system that provides quality care for all. NCHC is a nonpartisan, nonprofit organization of organizations. Our growing Coalition represents more than 80 participating organizations, including medical societies, businesses, unions, health care providers, faith-based associations, pension and health funds, insurers, and groups representing consumers, patients, women, … Read More...

PRESIDENT

John Rother

Interim CEO

Shawn Martin

CHAIRMAN

Jack Lewin
Principal and Founder
Lewin and Associates, LLC

MISSION

To bring together key stakeholders in order to achieve an affordable, high-value health care system for patients and consumers, for employers and other payers, and for taxpayers.

CONTACT US

900 16th Street NW, Suite 400
Washington, DC 20006
contactus@nchc.org

Connect With NCHC

  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Recent News & Posts

  • Update on Most Favored Nation Rule Litigation
  • NCHC 2020 Year In Review
  • NCHC Letter to President-Elect Biden’s Transition Team
  • NCHC STATEMENT ON BICAMERAL AND BIPARTISAN SURPRISE BILLING LEGISLATION, “NO SURPRISES ACT,”
  • The Impact of COVID-19 on Communities of Color

Recent Tweets

Tweets by NC_HC

Copyright © 2021 · Outreach Pro Theme on Genesis Framework · WordPress · Log in